Omeros has announced that the activation of clinical trial sites for patient enrolment is now in progress for its Phase III ...

Rhode Island may not be a large state, but what it lacks in size it makes up for in natural beauty -- such as along this ...

Shenzhen Zhongge Biotechnology Co. Ltd. has synthesized serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer, lymphangioleiomyomatosis and tuberous ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing ...

同时，生物医学通用绘图平台（GDP）于今年1月份在期刊Nucleic Acids Research发表的文章引用数达到了33次，表明了越来越多的科研人员在使用GDP，并给予了充分地认可！ 生物医学通用绘图平台GDP ...

Bloomingdale, IL— NOW has shared the latest results of its industry quality testing program investigating unfamiliar brands ...

Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – ...

Recent work in The EMBO Journal describes a new hybrid post-translational modification of proteins, composed of a poly-ubiquitin chain that is attached to a target protein via a mono-ADP-ribose (MAR) ...

SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...